These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 16820883

  • 1. Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells.
    Quick QA, Gewirtz DA.
    Int J Oncol; 2006 Aug; 29(2):407-12. PubMed ID: 16820883
    [Abstract] [Full Text] [Related]

  • 2. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, Lipson KE, Peschke P, Debus J, Abdollahi A, Huber PE.
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P.
    Blood Cells Mol Dis; 2005 Jul; 34(2):181-5. PubMed ID: 15727903
    [Abstract] [Full Text] [Related]

  • 5. Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
    Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R.
    Anticancer Res; 2009 Nov; 29(11):4575-8. PubMed ID: 20032406
    [Abstract] [Full Text] [Related]

  • 6. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S, Duensing A, Demetri GD, Fletcher JA.
    Oncogene; 2007 Nov 29; 26(54):7560-8. PubMed ID: 17546049
    [Abstract] [Full Text] [Related]

  • 7. High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway.
    Manov I, Bashenko Y, Eliaz-Wolkowicz A, Mizrahi M, Liran O, Iancu TC.
    J Pharmacol Exp Ther; 2007 Sep 29; 322(3):1013-22. PubMed ID: 17526808
    [Abstract] [Full Text] [Related]

  • 8. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
    Le Jeune N, Dubois F, Bin V, Perek N.
    Eur J Cancer; 2006 May 08; 42(8):1004-13. PubMed ID: 16564690
    [Abstract] [Full Text] [Related]

  • 10. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 08; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

  • 11. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 12. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 13. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation.
    Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB.
    Oncogene; 2007 Feb 22; 26(8):1201-12. PubMed ID: 16924232
    [Abstract] [Full Text] [Related]

  • 14. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M, Basciani S, Cherubini S, Mariani S, Migliaccio S, Arizzi M, Rosano G, Spera G, Gnessi L.
    Endocr Relat Cancer; 2007 Mar 22; 14(1):61-72. PubMed ID: 17395975
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 17. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L, Savranskaya L, Sweatman TW.
    Leuk Res; 2007 Aug 07; 31(8):1085-95. PubMed ID: 17187856
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y, Perdreau SA, Chatterjee P, Wang L, Kuan SF, Duensing A.
    Cancer Res; 2008 Nov 01; 68(21):9015-23. PubMed ID: 18974147
    [Abstract] [Full Text] [Related]

  • 19. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
    Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R.
    Exp Cell Res; 2008 Feb 01; 314(3):509-29. PubMed ID: 18061162
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.